Fig. 1: IL-34 and IL-34 receptors are upregulated in K/BxN serum-transfer mouse inflammatory arthritis and human RA. | Laboratory Investigation

Fig. 1: IL-34 and IL-34 receptors are upregulated in K/BxN serum-transfer mouse inflammatory arthritis and human RA.

From: IL-34 and protein-tyrosine phosphatase receptor type-zeta-dependent mechanisms limit arthritis in mice

Fig. 1

A Intra-synovial IL-34 and IL-34 receptor expression in arthritic versus normal WT mice [western blots (WB), n = 3-4/group]. B Serum IL-34 in arthritic WT versus similarly treated IL-34 KO mice (ELISA, n = 4/group). WT mouse serum (dotted line). C Intra-synovial IL-34 and PTPRZ binding in arthritic versus normal WT mice (Immunoprecipitation, n = 8 pooled/group, loading control: IgG). D Intra-synovial pFAK and FAK in arthritic versus normal WT mice [WB, same lysates as in C, n = 8 pooled/group]. E PTPRZ in BM derived Mo and Mø (WB, n = 4/group). F Intra-synovial IL-34 and CSF-1 in RA patients versus controls (immunostaining, n = 6/group). G PTPRZ and CSF-1R in RA versus controls (WB, n = 4/group). H Serum IL-34 and CSF-1 in RA versus controls (ELISA, n = 35-55/group). I PTPRZ in Mø and Mo from healthy controls (WB, n = 4/group). J Serum PTPRZ in RA versus osteoarthritis (OA) and healthy controls (ELISA, n = 15–25/group). K Serum PTPRZ levels in active RA versus patients in remission (n = 20/group). Panels (D, E, G, I), representative of three similar experiments. Data are means ± SEM. *P < 0.05. **P < 0.01. ***P < 0.001; two-tailed, Mann–Whitney U test.

Back to article page